Loading news...
TriSalus Life Sciences, Inc. (TLSI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors, today reported preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025. The Company anticipates fourth quarter 2025 revenues of approximately $13.2 million and ful.
TriSalus Life Sciences (NASDAQ: TLSI - Get Free Report) and Terumo (OTCMKTS:TRUMY - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, earnings, institutional ownership and valuation. Analyst Ratings This is a breakdown of recent
Stagezero Life Sciences (OTCMKTS:SZLSF - Get Free Report) and TriSalus Life Sciences (NASDAQ: TLSI - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings. Valuation and Earnings This table
TriSalus Life Sciences, Inc. (TLSI) Discusses Innovative Approaches for Thyroid Artery Embolization and Tumor-Targeted Therapies Transcript
AWM Investment Company Inc. bought a new stake in shares of TriSalus Life Sciences, Inc. (NASDAQ: TLSI) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,250,000 shares of the company's stock, valued at approximately $6,812,000. AWM Investment
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, announced today that it will host a virtual key opinion leader (KOL) event on Monday, December 15, 2025 at 2:00 PM ET featuring Juan C. Camacho, MD (Florida State University), who will join company management to discuss the unmet need and cur.
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, is pleased to announce the launch of the TriNav® XP Infusion System, the latest advancement in the company's portfolio of pressure-enabled drug delivery systems designed to improve therapy delivery in varying vascular environments. Building on the success of the TriNav platform, TriNav XP was.
TriSalus Life Sciences, Inc. ( TLSI ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Mary Szela - CEO, President & Director David Patience - Chief Financial Officer Richard Marshall Conference Call Participants Jeremy Feffer - Lifesci Advisors, LLC Nelson Cox - Lake Street Capital Markets, LLC, Research Division William Plovanic - Canaccord Genuity Corp., Research Division Junwoo Park - Cantor Fitzgerald & Co., Research Division Carl Byrnes - Northland Capital Markets, Research Division Justin Walsh - JonesTrading Institutional Services, LLC, Research Division Shaymus Contorno - Oppenheimer & Co. Inc., Research Division Presentation Operator Good afternoon, and welcome to TriSalus Life Sciences' Third Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded for replay purposes.
TriSalus Life Sciences, Inc. (TLSI) came out with a quarterly loss of $0.96 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.4 per share a year ago.
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces financial results for the quarter ended September 30, 2025, and provides an operation update. “TriSalus continued to deliver strong commercial performance in the third quarter, underscoring the growing clinica.
TriSalus Life Sciences, Inc. ( TLSI ) Discusses Pressure-Enabled Drug Delivery and Advances in Uterine Fibroid Embolization November 12, 2025 10:00 AM EST Company Participants Mary Szela - CEO, President & Director Richard Marshall Andrea Marasso Conference Call Participants Nicole Lamparello Francis Kang Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Justin Walsh - JonesTrading Institutional Services, LLC, Research Division Presentation Operator Good morning, and welcome to the TriSalus Life Sciences KOL event. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the TriSalus website following the conclusion of the event.
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will participate in the following investor conferences in November: Canaccord Genuity MedTech, Diagnostics and Digital Health.
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, announced today that it will host a virtual key opinion leader (KOL) event on Wednesday, November 12, 2025 at 10:00 AM ET featuring Nicole Lamparello, MD (Weill Cornell Medicine, New York-Presbyterian Hospital) and Francis Kang, MD (Universit.
TriSalus Life Sciences, Inc. (NASDAQ: TLSI - Get Free Report)'s share price fell 5.3% during trading on Wednesday. The company traded as low as $4.41 and last traded at $4.45. 111,590 shares were traded during mid-day trading, a decline of 8% from the average session volume of 121,560 shares. The stock had previously closed at
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, announced today that it will host a conference call and webcast on Thursday November 13, 2025 at 4:30 PM eastern time to discuss its financial results for the quarter ended September 30, 2025. A press release detailing the results will be iss.
TriSalus Life Sciences, Inc. (NASDAQ:TLSI ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 AM ET Company Participants David B. Patience - Chief Financial Officer Jeremy Feffer - Corporate Participant Mary T.
TriSalus Life Sciences, Inc. (TLSI) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.21 per share a year ago.
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, is pleased to announce the publication of clinical data evaluating the use of its proprietary Pressure-Enabled Drug DeliveryTM (PEDDTM) technology in thyroid parenchymal embolization, a new application for the treatment of patients with sympt.